News
Abbott Receives Positive Opinion for HUMIRA® in Ulcerative Colitis from EMA's CHMP: February 17,
Abbott Receives Positive Opinion for HUMIRA® in Ulcerative Colitis from EMA's CHMP
Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary | PRLog
Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary. ACR Response Criteria - An Endpoint Used in Clinical Trials of Most of the Blockbuster Drugs for Rheumatoid Arthritis - PR11795760
Vibex MTX: The Cherry On Top Of The Antares Investment Story - Seeking Alpha
< strong > By < a href='http://seekingalpha.com/author/smith-on-stocks' > Smith On Stocks < /a > : < /strong > < p > < b > Investment Thesis < /b > < /p > < p > I initiated < a href="http://seekingalpha.com/article/312158-antares-pharmaceuticals-a-buy-based-on-exceptional-new-product-outlook" >
Merck Co Inc Gets Positive CHMP Opinion for
WHITEHOUSE STATION, N.J.---- Positive Opinion Recommends Approval of the First and Only Anti-TNF Therapy in Pediatric Patients with Severely Active
Anti-TNF Therapies May Increase Malignant Melanoma Risks in People with Rheumatoid Arthritis
According to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago, people taking anti-tumor necrosis factor therapies to treat rheumatoid arthritis have a higher risk of developing malignant melanoma.
Merck to Develop Biosimilar with Korean Chemical Manufacturer - - BioPharm International
Merck & Co. and the biobusiness of Hanwha Chemical, a Korean chemical manufacturer, have formed an exclusive global agreement to develop and a commercialize a biosimilar of Enbrel (etanercept), a drug to treat moderate to severe plaque psoriasis, psoriatic arthritis, and moderate to severe
Merck to Develop Biosimilar with Korean Chemical Manufacturer - Pharmaceutical Technology
Merck and Hanwha Chemical have formed an exclusive global agreement to develop and a commercialize a biosimilar of Enbrel, a drug to treat moderate to severe plaque psoriasis, psoriatic arthritis, and moderate to severe rheumatoid arthritis.
'World Pre-filled Syringe Technology Revenues Will Reach $3.9bn in 2015' Says Visiongain Report |
SYS-CON Media, NJ, The world's leading i-technology media company on breaking technology news.
Merck and Hanwha Chemical establish global strategic collaboration | Pharma Asia
Merck and Hanwha Chemical Corporation announced that they have entered into an exclusive global agreement to develop and commercialize a candidate biosimilar form of Enbrel (etanercept). Under the terms of the agreement, Hanwha Chemical Corporation, through its Bio Business Unit, and Merck, through
Medical News: EULAR: No Increase in RA Death Rate With Etanercept - in Meeting Coverage, EULAR from
LONDON -- Short-term mortality rates among rheumatoid arthritis patients treated with etanercept (Enbrel) were no higher than among those treated with conventional anti-rheumatic drugs, according to r
Refine by Content Type:
Refine by Source:
- www.thelancet.com (237)
- download.thelancet.com (60)
- www.medpagetoday.com (56)
- www.webmd.com (53)
- www.em-consulte.com (44)
- arthritis.webmd.com (29)
- www.abbott.com (17)
- www.biospace.com (14)
- www.prlog.org (11)
- seekingalpha.com (11)
- www.australiandoctor.com.au (10)
- www.dddmag.com (7)
